Atrial fibrillation and stroke concepts and controversies

Stroke

Volumn 32, Issue 3, 2001, Pages

  Hart, R G ^a   Halperin, J L ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Anticoagulants; Aspirin; Atrial fibrillation; Cerebral embolism; Cerebrovascular disorders; Stroke

Indexed keywords

ACETYLSALICYLIC ACID; VITAMIN K GROUP; WARFARIN;

ANTICOAGULATION; CLINICAL TRIAL; DISEASE ASSOCIATION; HEART ATRIUM APPENDAGE; HEART ATRIUM FIBRILLATION; HUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; STROKE; AGED; BRAIN EMBOLISM; CEREBROVASCULAR ACCIDENT; CONTROLLED CLINICAL TRIAL; DRUG ANTAGONISM; META ANALYSIS; PATHOLOGY; PREVALENCE; RANDOMIZED CONTROLLED TRIAL; THROMBOSIS;

AGED; ASPIRIN; ATRIAL APPENDAGE; ATRIAL FIBRILLATION; CEREBROVASCULAR ACCIDENT; HUMANS; INTRACRANIAL EMBOLISM; PREVALENCE; RANDOMIZED CONTROLLED TRIALS; RISK ASSESSMENT; THROMBOSIS; VITAMIN K; WARFARIN;

EID: 0034745254     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.32.3.803     Document Type: Review

References (39)

1. Placebo-controlled, randomized trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: The Copenhagen AFASAK study
2. The Stroke Prevention in Atrial Fibrillation Study: Final results
3. The effect of low-dose warfarin on the risk of stroke in nonrheumatic atrial fibrillation
4. Atrial fibrillation and stroke: New ideas, persisting dilemmas
5. Atrial fibrillation and stroke: Revisiting the dilemmas
6. Echocardiographic assessment of the left atrial appendage
7. Pathophysiologic correlates of thromboembolism in nonvalvular atrial fibrillation: Reduced flow velocity in the left atrial appendage
8. Markers of thrombin and platelet activity in atrial fibrillation
9. Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: Analysis of 2012 participants in the SPAF I-III clinical trials
10. Transesophageal echocardiographic correlates of clinical risk of thromboembolism in nonvalvular atrial fibrillation
11. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: A meta-analysis
12. Secondary prevention of vascular events in patients with nonrheumatic atrial fibrillation and recent transient ischemic attack or minor ischemic stroke
13. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation. The Stroke Prevention in Atrial Fibrillation III randomised clinical trial
14. Indobufen versus warfarin in the secondary prevention of major vascular events in nonrheumatic atrial fibrillation
15. Mini-dose warfarin and aspirin in atrial fibrillation. Second Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulation Study (AFASAK 2)
16. Primary prevention of arterial thromboembolism in nonrheumatic atrial fibrillation in primary care: Randomised controlled trial comparing two intensities of coumarin with aspirin
17. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation. Stroke prevention in atrial fibrillation II study
18. Study does not have the power to show aspirin is as good as anticoagulation
19. Effectiveness of fixed minidose warfarin in the prevention of thromboembolism and vascular death in nonrheumatic atrial fibrillation
20. Optimal intensity of warfarin therapy for secondary prevention of stroke in patients with nonvalvular atrial fibrillation
21. Cardioembolic vs noncardioembolic strokes in atrial fibrillation: Frequency and effect of antithrombotic agents in the Stroke Prevention in Atrial Fibrillation studies
22. Ischemic stroke in patients with atrial fibrillation: Effect of aspirin according to stroke mechanism
23. Major bleeding during anticoagulation after cerebral ischemia: Patterns and risk factors. Stroke prevention in reversible ischemia trial (SPIRIT) and european atrial fibrillation trial (EAFT) study groups
24. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation
25. Intensity of anticoagulation to prevent stroke in patients with atrial fibrillation
26. Risk factors for intracranial hemorrhage in out-patients taking warfarin
27. Warfarin-associated hemorrhage and cerebral amyloid angiopathy: A genetic pathological study
28. Low-intensity anticoagulant therapy in elderly cardioembolic stroke patients with nonvalvular atrial fibrillation
29. Atrial fibrillation and thromboembolism: A decade of progress in stroke prevention
30. Assessment of three schemes for stratifying stroke risk in patients with nonvalvular atrial fibrillation
31. Stroke with intermittent atrial fibrillation: Incidence and predictors during aspirin therapy
32. Incidence of cerebral thromboembolic infarction associated with paroxysmal or persistent atrial fibrillation
33. Transesophageal echocardiographic correlates of thromboembolism in high-risk patients with atrial fibrillation
34. Transesophageal echocardiography to assess embolic risk in patients with atrial fibrillation
35. Prospective identification of patients with nonvalvular atrial fibrillation at low-risk of stroke daring treatment with aspirin
36. Warfarin use among ambulatory patients with nonvalvular atrial fibrillation
37. Temporal trends in the use of anticoagulants among older adults with atrial fibrillation
38. Prevalence of atrial fibrillation and eligibility for anticoagulants in the community
39. Implementing evidence based medicine in general practice: Audit and qualitative study of antithrombotic treatment for atrial fibrillation